The hot topic of the day is health insurance. The President is talking about it, the Senate is talking about it, and most importantly civilians are talking about it. No one can decide on the direction to take for a health care overhaul.

Health insurance in Illinois is a problem as it is in the rest of the US. An Illinois comprehensive health insurance plan is hard to come by. Many employers are cutting back or eliminating their health insurance plans.

This forces many individuals to shop for their own state of Illinois health insurance. In order to get an Illinois health insurance quote, one should visit healthinsurancepro.com. This is a site specifically devoted to individual health insurance Illinois.

They are able to offer alternatives to COBRA health insurance. They also can help you decide between HSAs vs. Co-Pay Plans. There are a multitude of plans to choose from and this site can help determine which is best for you.

Instead of waiting for the government to quit squabbling over a health care overhaul, individuals need to take action. Especially when looking at health insurance Illinois, individuals are at a crossroads regarding health care coverage.

Why pay full price on your next doctor visit? Instead consult the health insurance experts. You cannot get better prices for health insurance than at Benefit Solutions. Guaranteed by law!

They are experts in individual health insurance and understand the complexities of the business. It is time to seize the moment and take control of your individual health insurance. Let everyone else stand still and worry about the overhaul.

During the last 3 decades the Clinical Research industry has changed from a few small entrepreneurial providers offering a pressure valve to the pharmaceutical industry to a well established multi billion industry, growing by 10-15% annually and utilising around 100,000 specialists in a multitude of Clinical Research Organisations globally.

There has been a proliferation of companies, amalgamations and acquisitions which has lead to the structure of some very large international companies utilisaing as many as 15,000 employess globally. However, the market place is as different and as open for new ventures as it has been for decades; just very much bigger in overall size.

Unfortunately, a huge factor for advancement of this industry has been the ever increasing regulatory requirements rather than an enhancement in real innovation. Yet new approaches in drug development such as personalised medicines and the progression of biological medicines will certainly change the clinical research industry. It is likely however to continue to thrive but more in terms of overall size and variety.

Entering unexpored territories is the base of all research and as such requires a constantly broadening range of specialists who can contribute to the new challenges within drug development.

The industry has seen partnerships evolve. However the CRO market has not really adopted this concept.The processes by which clinical trial services are purchased have become smarter and more structured. The demand for standardised procedures dealing with large amounts of tests and data in some areas of full drug development have created a massive requiremenst and the subsequent formation of large and process driven CROs frequently supplying the major pharmaceutical companies. However, large processing units are not the most appropriate environments for true innovation and it is not surprising that big pharmaceutical companies constantly look for new alliances in the biotechnology and CRO industry.

Innovation is the product of excellence usually delivered by an individual. However, large development programmes are reliant on large infrastructures. These are very different needs that the industry has and it is unlikely that they will ever be efficiently met by any one CRO company.

However large the portfolio of a CRO may be, the forte of any large organisation is the ability to process large amounts of goods or clinical data management in a uniform way. The advantage of smaller companies is their ability to adapt to new challenges quickly and deliver true innovation. It follows that the diversity we currently see in the CRO market place is likely to continue providing the opportunities for new entrants to the market|However big the Clinical Research Industry is, the strong point of any formidable company is to have consistency with processing large amounts of products, services or data .

The increasing numbers of patients needed for trials, does require reassurances to the public with regard to the safety of those Clinical trials London. The number of regulations is likely to increase which will in turn create an increase in bureaucracy. This again will create a demand for larger organisations to process large amounts of data creating very large databases. Yet more regulations do not necessarily make research safer as the recent unprecedented tragedy at Northwick Park Hospital in London has shown. In this instance all relevant regulations were followed yet the information available was not evaluated in the appropriate way and as a consequence a far too high dose was given to a group of six previously healthy volunteers.  The challenge in controlling such complex issues is to find and involve a highly specialised expert in a particular field and to ensure that all available data is evaluated appropriately in the approval process. This represents a challenge, and in this instance, again, size will not be the answer.

Innovation and research require a large arsenal of research tools and services as well as an effectively functioning network, facilitating the access to and exchange of information, both on available services and expertise. It is the creation of these knowledge based networks which will create the most exciting opportunities for the future of a diverse and thriving CRO market.